Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹27.18B
Enterprise Value₹16.76K
Total Cash (Recent Filing)₹664.70M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)34.1
Beta1.05
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)17.86
Shares Outstanding44,686,905
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA near-zero leverage profile provides durable financial flexibility: it lowers solvency risk, supports countercyclical investment in lab capacity or technology, and preserves borrowing headroom for strategic M&A or working-capital needs, improving resilience across cycles.
Healthy Margin ProfileSustained mid-teens net margins and mid-30s EBITDA margins indicate structural profitability from specialized testing and clinical services. High implied operating leverage helps fund R&D and capex internally and supports long-term reinvestment and shareholder returns.
Consistent Revenue GrowthMulti-year top-line growth reflects durable demand for outsourced analytical and clinical services. Persistent revenue expansion supports better capacity utilization of labs and spreads fixed costs, underpinning earnings stability if secular outsourcing trends continue.
Bears Say
Margin VolatilityNotable swings in gross and operating margins (including a sharp shift from very high levels to lower levels) suggest mix, pricing or cost control variability. Such volatility undermines predictability of profits and complicates multi-quarter planning and margin expansion efforts.
Uneven Free Cash Flow / Cash ConversionIntermittent free cash flow (negative in 2024) and variable cash conversion indicate working-capital swings and episodic reinvestment needs. This reduces consistent internal funding for capex, limits steady dividend policy, and raises short-term liquidity planning risks.
Stagnant Returns ExpansionROE remaining mid-teens without meaningful expansion suggests limited operating leverage or competitive pressures preventing margin or asset-efficiency gains. Over time this can cap shareholder-value upside absent new service lines or productivity improvements.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹27.18B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Nov 14, 2026 which is in 101 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on Jul 20, 2026. The company reported ₹4.66 earnings per share for the quarter, missing the consensus estimate of ₹444.36 by -₹439.7.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.33%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,686,905 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.66 in its last earnings report, missing expectations of ₹444.36. Following the earnings report the stock price went down -5.085%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―